Cargando…

Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report

BACKGROUND: Previous studies have suggested the efficacy of HER2 antibody (trastuzumab) in scrotal Paget’s disease with HER2 amplification or overexpression. However, no report about the effectiveness of HER2 inhibitor (pyrotinib) in those patients has been provided until now. CASE PRESENTATION: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jin-Ju, Jiao, Xiao-Dong, Wu, Ying, Qin, Bao-Dong, Liu, Ke, Zang, Yuan-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342492/ https://www.ncbi.nlm.nih.gov/pubmed/32753879 http://dx.doi.org/10.2147/OTT.S244814

Ejemplares similares

Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report
por: Li, Suyao, et al.
Publicado: (2022)

Scrotal leiomyoma: An uncommon cause of chronic scrotal swelling
por: Adil, Hajar, et al.
Publicado: (2021)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Scrotal Extramammary Paget’s Disease in an Elderly Caucasian Male
por: Barrera, Jaimie M, et al.
Publicado: (2022)

Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
por: Hu, Wenyu, et al.
Publicado: (2023)

Interdisciplinary collaboration in a case of scrotal extramammary Paget’s disease
por: Piros, Éva Anna, et al.
Publicado: (2020)

Scrotal pyocele: Uncommon urologic emergency
por: Bruner, David I, et al.
Publicado: (2012)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
por: Qin, Bao-Dong, et al.
Publicado: (2018)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
por: Chen, Hao, et al.
Publicado: (2023)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant
por: Gao, Zhichao, et al.
Publicado: (2021)

Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
por: Huang, Tingting, et al.
Publicado: (2020)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study
por: Chen, Jiaxin, et al.
Publicado: (2022)

Inguinal and scrotal extramammary Paget’s disease: (18)F-FDG PET/CT imaging
por: Tung, Kelly, et al.
Publicado: (2018)

Tumor Wide Horizontal Invasion Predicts Local Recurrence for Scrotal Extramammary Paget’s Disease
por: Wang, Lujia, et al.
Publicado: (2017)

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
por: Li, Hong-Shuai, et al.
Publicado: (2020)

An Uncommon Osseous Frontal Sinus Tumor: Monostotic Paget's Disease
por: Labajian, Varant, et al.
Publicado: (2013)

Bladder Carcinoma Presenting as Paget's Disease of Vulva: An Uncommon Entity
por: Mehta, Anurag, et al.
Publicado: (2018)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
por: Qi, Xiaowei, et al.
Publicado: (2023)

Scrotal extratesticular schwannoma: A common tumor at an uncommon location
por: Pujani, M, et al.
Publicado: (2018)

Scrotal Labia – An Uncommon Presentation of Vulvar Lichen Simplex Chronicus
por: Verma, Shyam Bhanushankar
Publicado: (2021)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
por: Liu, Jing, et al.
Publicado: (2021)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Li, Chao, et al.
Publicado: (2021)

Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
por: Yin, Sha, et al.
Publicado: (2022)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
por: Ding, Kailin, et al.
Publicado: (2021)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p7n9rfkira1dubpch8nsak9l25